John Hussman's INBX Position Overview
John Hussman (via Hussman Strategic Advisors, Inc.) currently holds 31,500 shares of Inhibrx Biosciences, Inc. (INBX) worth $2.98 M, representing 0.69% of the portfolio. First purchased in 2026-Q2, this recently established position has been held for 1 quarters.
Based on recent 13F filings, John Hussman has initiated a new position in INBX, representing a fresh investment thesis on this company. Insufficient history to summarize additions or reductions.
Analysis based on 13F filings available since 2013 Q2
John Hussman's Inhibrx Biosciences (INBX) Holding Value Over Time
Track share changes against reported price movement
Quarterly Inhibrx Biosciences (INBX) Trades by John Hussman
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2026 | +31,500 | New Buy | 31,500 | $94.75 |
John Hussman's Inhibrx Biosciences Investment FAQs
John Hussman first purchased Inhibrx Biosciences, Inc. (INBX) in Q2 2026, acquiring 31,500 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
John Hussman has held Inhibrx Biosciences, Inc. (INBX) for 1 quarters since Q2 2026.
John Hussman's largest addition to Inhibrx Biosciences, Inc. (INBX) was in Q2 2026, adding 31,500 shares worth $2.98 M.
According to the latest 13F filing for Q2 2026, John Hussman's firm, Hussman Strategic Advisors, Inc., owns 31,500 shares of Inhibrx Biosciences, Inc. (INBX), valued at approximately $2.98 M.
As of the Q2 2026 filing, Inhibrx Biosciences, Inc. (INBX) represents approximately 0.69% of John Hussman's publicly disclosed stock portfolio, making it one of their key holdings.
John Hussman's peak holding in Inhibrx Biosciences, Inc. (INBX) was 31,500 shares, as reported at the end of Q2 2026.